Acesion Pharma ApS

Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Existing drug therapies generally have a limited effect or are associated with risk of serious adverse events, and there is therefore a considerable patient need for developing better and safer drugs. Inhibition of SK channels, an ion channel with relevance for regulating the heart rhythm, constitute a new and promising principle for the treatment of AF.

Contact name:

Ulrik S. Sørensen (CEO)

Address:

Ole Maaløes Vej 3, 2200 København N, Denmark

If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2016 Danskbiotek. All rights reserved.